104
[2] Janssens F., Torremans J., Janssen M., Stokbroekx R.A., Luyckx
M., Janssen P.A.J., J. Med. Chem. 28 (1985) 1925–1933.
were constructed. Mepyramine and astemizole [27, 28]
were employed as a reference drugs for H1-histamine
antagonism, and atropine was used as standard for
acetylcholine antagonism.
The pA2 values for the competitive H1-antagonists
were calculated in accordance with the method described
by Schild [40, 41], using the calculation program re-
ported by Tallarida and Murray [42]. The Student’s t-test
was used to estimate statistical significance.
[3] Janssens F., Torremans J., Janssen M., Stokbroekx R.A., Luyckx
M., Janssen P.A.J., J. Med. Chem. 28 (1985) 1943–1947.
[4] Iemura I., Kawashima T., Fukuda T., Ito K., Tsukamoto G., J. Med.
Chem. 29 (1986) 1178–1183.
[5] Ife R.J., Catchpole K.W., Durant G.J., Ganellin C.R., Harvey C.A.,
Meeson M.L., Owen D.A.A., Parsons M.E., Slingsby B.P., Theobald C.J.,
Eur. J. Med. Chem. 24 (1989) 249–258.
[6] Sleevi M.C., Cale A.D., Gero T.W., Jaques L.W., Welstead W.J.,
Johnson A.F., Kilpatrick B.F., Demian I., Nolan J.C., Jenkins H., J. Med.
Chem. 34 (1991) 1314–1328.
6.3.3. In vivo test – Histamine-induced coutaneous
vascular permeability
[7] Zhang M.Q., ter Laak A.M., Timmerman H., Eur. J. Med. Chem.
28 (1993) 165–173.
The ability of compounds under investigation to inhibit
histamine-induced skin weal formation was investigated.
Anaesthetized male Sprague Dawley rats, weighing
approximately 150 g, were used. The products were given
as aqueous solutions, at a constant volume of 5 mL /kg
subcutaneously, in doses from 2 to 10 mg/kg. The same
volume of the vehicle was administered to control ani-
mals. The agents to be assayed were administered 45 min
before an intravenous injection of 0.30 mL 0.9% sodium
chloride containing 3.75 mg Evans’ blue dye. This treat-
ment was immediately followed by two distinct intracu-
taneous injections on the shaved backs of 50 µL saline-
buffered solution containing 10 µg histamine. The
reaction was evaluated after 30 min.
[8] Carceller E., Merlos M., Giral M., Balsa D., Almansa C., Bartrolí
J., García-Rafanell J., Forn J., J. Med. Chem. 37 (1994) 2697–2703.
[9] Abou-Gharbia M., Moyer J.A., Nielsen S.T., Webb M., Patel U., J.
Med. Chem. 38 (1995) 4026–4032.
[10] Iawasaki N., Ohashi T., Musoh K., Nishino H., Kado N., Yasuda
S., Kato H., Ito Y., J. Med. Chem. 38 (1995) 496–507.
[11] Janssens F., Torremans J., Janssen M., Stokbroekx R.A., Luyckx
M., Janssen P.A.J., J. Med. Chem. 28 (1985) 1934–1943.
[12] Wauquier A., Niemegeers C.J.E., Eur. J. Pharmacol. 72 (1981)
245–248.
[13] Van Wauwe J., Awouters F.H.L., Niemegeers C.J.E., Janssens F.,
VanNueten J.M., Janssen P.A.J., Arch. Int. Pharmacodyn. 251 (1981)
39–51.
[14] Awouters F.H.L., Niemegeers C.J.E., Janssen P.A.J., Arzneim.
Forsch. 33 (1983) 381–388.
[15] Iemura R., Ohtaka H., Chem. Pharm. Bull. 37 (1989) 967–972.
Animals were sacrificed, then the skin was removed
and biopsies were taken around the injection sites. The
dye contained in each cutaneous fragment was extracted
and, after centrifugation, the optical density of the super-
natant was measured at 620 nm. Quantization of Evans’
blue dye was calculated by standard calibration curves
obtained by injecting the dye intradermally at various
concentrations in other animals.
[16] ter Laak A.M., Venhorts J., Donné-op den Kelder G.M., Timmer-
man H., J. Med. Chem. 38 (1995) 3351–3360.
[17] Da Settimo A., Primofiore G., Da Settimo F., Calzolari L.,
Cazzulani P., Passoni A., Tofanetti O., Eur. J. Med. Chem. 27 (1992)
395–400.
[18] Primofiore G., Marini A.M., Da Settimo F., Franzone J.S., Mason
U., Reboani M.C., Cirillo R., Eur. J. Med. Chem. 23 (1988) 397–401.
[19] Da Settimo A., Primofiore G., Marini A.M., Ferrarini P.L., Fran-
zone J.S., Cirillo R., Reboani M.C., Eur. J. Med. Chem. 23 (1988) 21–24.
The amount of dye that leaked into the tissue was
considered the parameter of increased vascular perme-
ability.
The effects of test drugs were expressed as percentage
inhibition of the dye amounts extracted from the control
group.
[20] Da Settimo A., Primofiore G., Da Settimo F., Marini A.M.,
Novellino E., Greco G., Martini C., Giannaccini G., Lucacchini A., J. Med.
Chem. 39 (1996) 5083–5091.
[21] Saxena A.K., Ram S., Prog. Drug. Res. 23 (1979) 199–232.
[22] Saxena M., Agarwal S.K., Patnaik G.K., Saxena A.K., J. Med.
Chem. 33 (1990) 2970–2976.
[23] Rubottom G.M., Chabala J.C., Synthesis 566. (1972)
[24] Young E.H.P., J. Chem. Soc. (1958) 3493–3496.
[25] Andreani A., Rambaldi M., Bonazzi D., Andreani F., Bossa R.,
Galatulas I., Arch. Pharm. 317 (1984) 847–851.
Acknowledgements
[26] Kamei C., Mio M., Izushi K., Kitazumi K., Tsujimoto S., Fujisawa
K., Adachi Y., Tasaka K., Arzneim. Forsch. 41 (1991) 932–936.
This work was supported by grants from the Ministry
of University and Scientific and Technological Research
(MURST) (Research fund 60%).
[27] Kii Y., Inui A., Ito T., Arch. Int. Pharmacodyn. 331 (1996) 59–73.
[28] Pedersen L.G., Hoskins R.E., Cable H., J. Pharm. Pharmacol. 23
(1971) 216–218.
[29] Naruto S., Motoc I., Marshall G.R., Eur. J. Med. Chem. 20 (1985)
529–532.
References
[30] Borea P.A., Bertolasi V., Gilli G., Arzneim. Forsch. 36 (1986)
895–899.
[1] ter Laak A.M., van Droodge M.J., Timmerman H., Donnè-op den
Kelder M., Quant. Struct. Act. Relat. 11 (1992) 348–363.
[31] Najer H., Giudicelli R., Sette J., Bull. Soc. Chim. (1962) 556–559.